臨床試験用品市場 : 2028年までの世界予測

Report Overview

The global clinical trial supplies market size is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9% during the forecast period. Factors such as Increasing number of clinical trials, Growing product pipeline, and Increasing decentralization of clinical trials are likely to have positive impact on the market growth.

“The logistics and distribution segment held the dominant share in the clinical trial supplies market”
Based on services, the global clinical trial supplies market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.

“Phase II segment accounted for the largest share of the phase segment in 2022.”
Based on phase, the clinical trial supplies market is segmented into phase I, phase II, phase III, phase IV, BA/BE studies. In 2022, the phase II segment accounted for the largest share of the clinical trial supplies market. The segment held the dominant share in the market owing to various factors such as increasing the number of registration in clinical trials and the rising R&D investment by pharmaceutical and biotechnologies company for new cancer drug development.

“Asia Pacific region is likely to grow at a faster pace in the clinical trial supplies market.”
The clinical trial supplies market region is segmented into North America, Europe, Asia Pacific, Latin America Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing number of registered clinical trials. The increasing decentralization of clinical trials from China, India, and Japan due to presence of prominent players are engaged in providing services for clinical trial, supports market growth in the Asia Pacific. 

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%, and Demand Side – 20%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Catalent, Inc. (US)
• Eurofins (France)
• Piramal Pharma Solutions (India)
• PRA Health Sciences (Subsidiary of Icon Plc) (US)
• Marken (Subsidiary of UPS) (US)
• Parexel International (MA) Corporation (US)
• Biocair (UK)
• Almac Group (UK)
• Sharp Services, LLC (US)
• PCI Pharma Services (US)
• Nuvisan (Germany)
• Lonza Group (Switzerland)
• OCT Group LLC. (Latvia)
• Corex Logistics (Ireland)
• Acnos Pharma GMBH (Germany)
• Clinical Services International (UK)
• KLIFO A/S (Denmark)
• Clinigen Limited (UK)
• Ancillare LP (US)
• N-SIDE (Belgium)
• ADAllen Pharma (UK)
• Durbin ( Part of the Uniphar Group) (UK)
• Recipharm AB (Sweden)
• IPS Pharma (UK)

Research Coverage:
This report provides a detailed picture of the clinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments, such as service, phase, type, therapeutic area, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies, Increasing number of clinical trials, Growing decentralization of clinical trials, Rising prevalence of orphan and rare diseases, Increasing outsourcing activities in emerging Asian economies), restraints ( High cost of drug development), opportunities (Growth opportunities in emerging markets, Increased investments in development of biologics and biosimilars, Rising demand for specialized testing services) and challenges (High Cost of Clinical Trials) are influencing the growth of clinical trial supplies market.
• Service Development/Innovation: Detailed insights on newly launched services of the clinical trial supplies market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the clinical trial supplies market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial supplies market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include  Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US),

Table of Contents

1            INTRODUCTION            40

1.1         STUDY OBJECTIVES      40

1.2         MARKET DEFINITION   40

1.2.1      INCLUSIONS & EXCLUSIONS     41

1.3         MARKET SCOPE             42

1.3.1      MARKETS COVERED     42

1.3.2      YEARS CONSIDERED     42

1.4         CURRENCY CONSIDERED          43

1.5         RESEARCH LIMITATIONS           43

1.6         STAKEHOLDERS            43

1.7         SUMMARY OF CHANGES            44

1.8         RECESSION IMPACT      44

2            RESEARCH METHODOLOGY     45

2.1         RESEARCH APPROACH 45

FIGURE 1           RESEARCH DESIGN       45

2.1.1      PRIMARY RESEARCH     46

FIGURE 2           CLINICAL TRIAL SUPPLIES MARKET: PRIMARY RESPONDENTS              46

2.1.2      SECONDARY DATA       47

2.2         MARKET SIZE ESTIMATION       48

FIGURE 3           CLINICAL TRIAL SUPPLIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 48

FIGURE 4           MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022             49

2.2.1      INSIGHTS FROM PRIMARY         50

FIGURE 5           MARKET SIZE VALIDATION FROM PRIMARY EXPERTS   50

2.2.2      SEGMENTAL ASSESSMENT (BY SERVICE, PHASE, TYPE, THERAPEUTIC AREA, END USER, AND REGION)             51

FIGURE 6           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       51

2.3         GROWTH RATE ASSUMPTIONS 52

FIGURE 7           CLINICAL TRIAL SUPPLIES MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS           52

FIGURE 8           CLINICAL TRIAL SUPPLIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    53

FIGURE 9           DATA TRIANGULATION METHODOLOGY         54

2.4         STUDY ASSUMPTIONS  54

2.5         RISK ANALYSIS 55

2.6         RECESSION IMPACT ANALYSIS 55

TABLE 1             GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)         56

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  56

TABLE 3             US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)  56

3            EXECUTIVE SUMMARY 57

FIGURE 10         CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION) 57

FIGURE 11         CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 58

FIGURE 12         CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)     58

FIGURE 13         CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)     59

FIGURE 14         CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION) 59

FIGURE 15         GEOGRAPHICAL SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET            60

4            PREMIUM INSIGHTS      61

4.1         CLINICAL TRIAL SUPPLIES MARKET OVERVIEW             61

FIGURE 16         RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH        61

4.2         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2022)           62

FIGURE 17         SMALL-MOLECULE DRUGS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIAL SUPPLIES MARKET IN 2022              62

4.3         CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2023 VS. 2028              63

FIGURE 18         LOGISTICS & DISTRIBUTION SERVICES TO CONTINUE TO DOMINATE MARKET IN 2028     63

4.4         CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2022 63

FIGURE 19         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022     63

4.5         CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           64

FIGURE 20         ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028         64

5            MARKET OVERVIEW     65

5.1         INTRODUCTION            65

5.2         MARKET DYNAMICS     65

FIGURE 21         CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    65

5.3         CLINICAL TRIAL SUPPLIES MARKET: IMPACT ANALYSIS             66

5.3.1      DRIVERS            66

5.3.1.1   Increasing R&D investments by biopharma companies 66

TABLE 4             R&D INVESTMENTS BY MAJOR PLAYERS (2022) 67

5.3.1.2   Growing number of clinical trials     67

FIGURE 22         NUMBER OF REGISTERED CLINICAL TRIALS (2011–2022)              67

FIGURE 23         ONGOING CLINICAL TRIALS, BY PHASE (% SHARE), 2022              68

5.3.1.3   Growing decentralization of clinical trials       68

5.3.1.4   Rising prevalence of orphan and rare diseases 69

FIGURE 24         OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023)  69

FIGURE 25         PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHED WITH ORPHAN DRUG DESIGNATION, 2012–2022             70

5.3.1.5   Increasing outsourcing activities in emerging Asian economies  70

5.3.2      RESTRAINTS     71

5.3.2.1   High cost of drug development        71

5.3.3      OPPORTUNITIES           72

5.3.3.1   Growth opportunities in emerging markets    72

5.3.3.2   Increased investments in development of biologics and biosimilars          72

FIGURE 26         TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015–2022)     73

TABLE 5             LIST OF BIOLOGICS APPROVED BY US FDA, 2022            73

FIGURE 27         BIOSIMILAR APPROVALS AND LAUNCHES (2015–2022)  74

5.3.3.3   Rising demand for specialized testing services              74

5.3.4      CHALLENGES   75

5.3.4.1   High cost of clinical trials   75

5.4         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75

FIGURE 28         REVENUE SHIFT AND NEW REVENUE POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS       75

5.5         PRICING ANALYSIS        76

5.5.1      INDICATIVE PRICING ANALYSIS OF OVERALL CLINICAL TRIALS, BY PHASE. 76

TABLE 6             PHASE III ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES)           77

TABLE 7             PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN)     77

5.6         TECHNOLOGY ANALYSIS           78

5.6.1      INTERACTIVE RESPONSE TECHNOLOGY (IRT) 78

5.7         VALUE CHAIN ANALYSIS            79

FIGURE 29         VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE     79

5.8         ECOSYSTEM ANALYSIS 80

5.9         SUPPLY CHAIN ANALYSIS          81

TABLE 8             CLINICAL TRIAL SUPPLIES MARKET: SUPPLY CHAIN ANALYSIS              81

5.10       KEY CONFERENCES & EVENTS IN 2023–2024       82

TABLE 9             CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS          82

5.11       REGULATORY ANALYSIS            83

5.11.1    REGULATORY LANDSCAPE FOR CLINICAL TRIAL SUPPLIES       83

5.11.1.1 North America     83

5.11.1.2 Europe  84

5.11.1.3 Asia Pacific          84

5.11.1.4 Rest of the World 85

5.11.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          86

TABLE 10           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         86

TABLE 11           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87

TABLE 12           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         88

TABLE 13           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         89

TABLE 14           MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         89

5.12       PORTER’S FIVE FORCES ANALYSIS         90

TABLE 15           CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS          90

5.12.1    THREAT OF NEW ENTRANTS    90

5.12.2    THREAT OF SUBSTITUTES         90

5.12.3    BARGAINING POWER OF SUPPLIERS     90

5.12.4    BARGAINING POWER OF BUYERS           91

5.12.5    DEGREE OF COMPETITION       91

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          92

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         92

FIGURE 30         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SUPPLY SERVICES       92

5.13.2    BUYING CRITERIA FOR CLINICAL TRIAL SUPPLY SERVICES        93

FIGURE 31         KEY BUYING CRITERIA FOR END USERS              93

6            CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE           94

6.1         INTRODUCTION            95

TABLE 16           CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 95

6.2         LOGISTICS & DISTRIBUTION     95

6.2.1      INCREASING COMPLEXITY AND EVOLVING TREATMENT PROTOCOLS TO DRIVE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES            95

TABLE 17           CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2021–2028 (USD MILLION)           96

TABLE 18           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)          96

TABLE 19           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)   97

TABLE 20           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)          97

TABLE 21           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)          98

6.3         STORAGE & RETENTION            98

6.3.1      GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH  98

TABLE 22           CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2021–2028 (USD MILLION)  99

TABLE 23           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              99

TABLE 24           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)            100

TABLE 25           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              100

TABLE 26           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              101

6.4         PACKAGING, LABELING, AND BLINDING            101

6.4.1      RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE SEGMENTAL GROWTH          101

TABLE 27           CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2021–2028 (USD MILLION)              102

TABLE 28           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 102

TABLE 29          EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              103

TABLE 30           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 103

TABLE 31           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LABELING, AND BLINDING SERVICES, COUNTRY, 2021–2028 (USD MILLION)              104

6.5         MANUFACTURING        104

6.5.1      GROWING FOCUS OF COMPANIES ON INCREASING MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH         104

TABLE 32           CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2021–2028 (USD MILLION)           105

TABLE 33           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 105

TABLE 34           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 106

TABLE 35           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 106

TABLE 36           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, COUNTRY, 2021–2028 (USD MILLION)      107

6.6         COMPARATOR SOURCING         107

6.6.1      INTENSE MARKET COMPETITION AND RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH 107

TABLE 37           CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2021–2028 (USD MILLION)    108

TABLE 38           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              108

TABLE 39           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              109

TABLE 40           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              109

TABLE 41           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)              110

6.7         OTHER SERVICES          110

TABLE 42           CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2021–2028 (USD MILLION)       111

TABLE 43           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)       111

TABLE 44           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)       112

TABLE 45           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)       112

TABLE 46           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)       113

7            CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 114

7.1         INTRODUCTION            115

TABLE 47           CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          115

7.2         PHASE III           115

7.2.1      LARGE PATIENT POPULATION ASSOCIATED WITH PHASE III TRIALS TO DRIVE DEMAND      115

TABLE 48           CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 116

TABLE 49           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)   116

TABLE 50           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)       117

TABLE 51           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)  117

TABLE 52           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)   118

7.3         PHASE II             118

7.3.1      ABILITY OF PHASE II CLINICAL TRIALS TO PROVIDE CLARITY ON EFFECTIVENESS AND SAFETY OF DRUGS TO DRIVE MARKET GROWTH 118

TABLE 53           CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 119

TABLE 54           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)     119

TABLE 55           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)       120

TABLE 56           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)    120

TABLE 57           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)     121

7.4         PHASE I              121

7.4.1      IMPORTANCE OF QUALITY CLINICAL TRIAL SUPPLIES IN PHASE I CLINICAL TRIALS TO BOOST MARKET  121

TABLE 58           CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 121

TABLE 59           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)      122

TABLE 60           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)       122

TABLE 61           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)     123

TABLE 62           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)      123

7.5         PHASE IV           124

7.5.1      INCREASING NUMBER OF STUDIES UNDER PHASE IV TRIAL TO SUPPORT GROWTH      124

TABLE 63           CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2021–2028 (USD MILLION) 124

TABLE 64           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)   124

TABLE 65           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)       125

TABLE 66           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)  125

TABLE 67           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2021–2028 (USD MILLION)   126

7.6         BA/BE STUDIES 126

7.6.1      INCREASING PATENT EXPIRATION TO INCREASE DEMAND FOR BA/BE STUDIES            126

TABLE 68           CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2021–2028 (USD MILLION)       127

TABLE 69           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)          127

TABLE 70           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)        128

TABLE 71           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)        128

TABLE 72           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)          129

8            CLINICAL TRIAL SUPPLIES MARKET, BY TYPE   130

8.1         INTRODUCTION            131

TABLE 73           CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          131

8.2         SMALL-MOLECULE DRUGS       131

8.2.1      LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH        131

TABLE 74           CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION) 132

TABLE 75           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)    132

TABLE 76           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)    133

TABLE 77           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)    133

TABLE 78           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)    134

8.3         BIOLOGIC DRUGS         134

8.3.1      RELATIVELY LOW RATE OF ATTRITION OF BIOLOGIC DRUGS COMPARED TO SMALL-MOLECULE DRUGS TO BOOST GROWTH           134

TABLE 79           CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2021–2028 (USD MILLION)       135

TABLE 80           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)      135

TABLE 81           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)           136

TABLE 82           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)      136

TABLE 83           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2021–2028 (USD MILLION)      137

8.4         MEDICAL DEVICES        137

8.4.1      INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO SUPPORT GROWTH      137

TABLE 84           CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2021–2028 (USD MILLION)  138

TABLE 85           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)    138

TABLE 86           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)        139

TABLE 87           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)    139

TABLE 88           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2021–2028 (USD MILLION)    140

9            CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA   141

9.1         INTRODUCTION            142

TABLE 89           CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)          142

9.2         ONCOLOGY      142

9.2.1      GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH          142

FIGURE 32         US CANCER INCIDENCE IN MALES, BY TYPE (2022)        143

FIGURE 33         US CANCER INCIDENCE IN FEMALES, BY TYPE (2022)    143

FIGURE 34         GLOBAL ONCOLOGY-RELATED CLINICAL TRIALS, 2010–2021 (THOUSAND)   144

TABLE 90           NEW FDA-APPROVED ONCOLOGY DRUGS (2023)           145

TABLE 91           CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)       146

TABLE 92           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  146

TABLE 93          EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)            147

TABLE 94           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  147

TABLE 95           LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  148

9.3         INFECTIOUS DISEASES 148

9.3.1      INCREASING CASES OF INFECTIOUS DISEASES TO ACCELERATE EFFORTS TO DEVELOP NEW DRUGS     148

TABLE 96           CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)           149

TABLE 97           NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)            149

TABLE 98           EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)            150

TABLE 99           ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)            150

TABLE 100         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)            151

9.4         NEUROLOGY    151

9.4.1      GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR NEUROLOGY RESEARCH TO DRIVE GROWTH   151

TABLE 101         LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)   152

TABLE 102         CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)       152

TABLE 103         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153

TABLE 104         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 153

TABLE 105         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 154

TABLE 106         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 154

9.5         METABOLIC DISORDERS           155

9.5.1      INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH         155

FIGURE 35         ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 155

TABLE 107         CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)       156

TABLE 108         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)        157

TABLE 109         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)   157

TABLE 110         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)        158

TABLE 111         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)        158

9.6         IMMUNOLOGY 159

9.6.1      CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL DEMAND FOR CLINICAL TRIAL SUPPLIES   159

TABLE 112         LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)   159

TABLE 113         CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)       160

TABLE 114         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)           160

TABLE 115         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)           161

TABLE 116         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)           161

TABLE 117         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)           162

9.7         CARDIOLOGY  162

9.7.1      GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH     162

TABLE 118         LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023)   163

TABLE 119         CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)       164

TABLE 120         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)             164

TABLE 121         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)             165

TABLE 122         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)             165

TABLE 123         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)             166

9.8         GENETIC & RARE DISEASES       166

9.8.1      INCREASING R&D FOR DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE DEMAND             166

TABLE 124         CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY REGION, 2021–2028 (USD MILLION)           167

TABLE 125         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)    167

TABLE 126         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)           168

TABLE 127         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)    168

TABLE 128         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENETIC & RARE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)    169

9.9         OTHER THERAPEUTIC AREAS   169

TABLE 129         LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)     170

TABLE 130         CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)   170

TABLE 131         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)              171

TABLE 132         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)             171

TABLE 133         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)             172

TABLE 134         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)              172

10          CLINICAL TRIAL SUPPLIES MARKET, BY END USER        173

10.1       INTRODUCTION            174

TABLE 135         CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION) 174

10.2       PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES   174

10.2.1    INCREASING OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMA & BIOTECH COMPANIES TO BOOST MARKET 174

TABLE 136         CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 175

TABLE 137         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 175

TABLE 138         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 176

TABLE 139         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 176

TABLE 140         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 177

10.3       CONTRACT RESEARCH ORGANIZATIONS          177

10.3.1    INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS           177

TABLE 141         CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)     177

TABLE 142         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)          178

TABLE 143         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178

TABLE 144         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)          179

TABLE 145         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)          179

10.4       MEDICAL DEVICE COMPANIES 179

10.4.1    INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET            179

TABLE 146         CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2021–2028 (USD MILLION)      180

TABLE 147         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)              180

TABLE 148         EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)  181

TABLE 149         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)              181

TABLE 150         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)              182

11          CLINICAL TRIAL SUPPLIES MARKET, BY REGION            183

11.1       INTRODUCTION            184

TABLE 151         CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2021–2028 (USD MILLION) 184

11.2       NORTH AMERICA          184

FIGURE 36         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT        185

TABLE 152         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    185

TABLE 153         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       186

TABLE 154         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          186

TABLE 155         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)             187

TABLE 156         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             187

TABLE 157         NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)    188

11.2.1    US         188

11.2.1.1 Increasing R&D investments to drive market growth in US        188

TABLE 158         US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 189

TABLE 159         US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 189

TABLE 160         US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190

TABLE 161         US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            190

TABLE 162         US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)     191

11.2.2    CANADA            191

11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth           191

TABLE 163         CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          192

TABLE 164         CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     192

TABLE 165         CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     193

TABLE 166         CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             193

TABLE 167         CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          194

11.2.3    NORTH AMERICA: RECESSION IMPACT 194

11.3       EUROPE             195

TABLE 168         EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          195

TABLE 169         EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          196

TABLE 170         EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     196

TABLE 171         EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     197

TABLE 172         EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             197

TABLE 173         EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          198

11.3.1    GERMANY         198

11.3.1.1 Growing number of sponsored trials to boost demand for clinical trial supplies in Germany             198

TABLE 174         GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          199

TABLE 175         GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          199

TABLE 176         GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     200

TABLE 177         GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             200

TABLE 178         GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          201

11.3.2    UK         201

11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth           201

TABLE 179         UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)     202

TABLE 180         UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION) 202

TABLE 181         UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 203

TABLE 182         UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            203

TABLE 183         UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)     204

11.3.3    FRANCE             204

11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France   204

TABLE 184         FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          205

TABLE 185         FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     205

TABLE 186         FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     206

TABLE 187         FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             206

TABLE 188         FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          207

11.3.4    ITALY   207

11.3.4.1 Increasing number of drug approvals to drive market for clinical trial supplies in Italy       207

TABLE 189         ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)     207

TABLE 190         ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     208

TABLE 191         ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 208

TABLE 192         ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            209

TABLE 193         ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          209

11.3.5    SPAIN   210

11.3.5.1 Increasing biologics production to support market growth in Spain          210

TABLE 194         SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)     210

TABLE 195         SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     211

TABLE 196         SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 211

TABLE 197         SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            212

TABLE 198         SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          212

11.3.6    SWITZERLAND 213

11.3.6.1 Growing R&D efforts to provide growth opportunities for clinical trial supplies market in Switzerland        213

TABLE 199         SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       213

TABLE 200        SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          214

TABLE 201         SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          214

TABLE 202         SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             215

TABLE 203         SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             215

11.3.7    NETHERLANDS 216

11.3.7.1 Increasing pharmaceutical production to boost clinical trial supplies market in Netherlands         216

TABLE 204         NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       216

TABLE 205         NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          217

TABLE 206         NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          217

TABLE 207         NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             218

TABLE 208         NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             218

11.3.8    REST OF EUROPE           219

TABLE 209         REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       220

TABLE 210         REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          220

TABLE 211         REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)             221

TABLE 212         REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             221

TABLE 213         REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             222

11.3.9    EUROPE: RECESSION IMPACT   222

11.4       ASIA PACIFIC    223

FIGURE 37         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT              223

TABLE 214         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    224

TABLE 215        ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          224

TABLE 216         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          225

TABLE 217         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          225

TABLE 218         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             226

TABLE 219         ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             226

11.4.1    CHINA  227

11.4.1.1 Favorable government regulations to boost market growth in China         227

TABLE 220         CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)     227

TABLE 221         CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     228

TABLE 222         CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     228

TABLE 223         CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            229

TABLE 224         CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          229

11.4.2    JAPAN  230

11.4.2.1 Government initiatives for drug innovation to support market growth      230

TABLE 225         JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)     231

TABLE 226         JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     231

TABLE 227         JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     232

TABLE 228         JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            232

TABLE 229         JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          233

11.4.3    INDIA   233

11.4.3.1 Low manufacturing costs and skilled workforce to attract outsourcing and investments to India           233

TABLE 230         INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)     234

TABLE 231         INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     234

TABLE 232         INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 235

TABLE 233         INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            235

TABLE 234         INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          236

11.4.4    AUSTRALIA       236

11.4.4.1 Presence of many research institutes conducting clinical trials to boost market growth   236

TABLE 235         AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          237

TABLE 236         AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          237

TABLE 237         AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          238

TABLE 238         AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             238

TABLE 239        AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          239

11.4.5    SOUTH KOREA 239

11.4.5.1 Government investments to contribute to market growth in South Korea 239

TABLE 240         SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       240

TABLE 241        SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          240

TABLE 242         SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          241

TABLE 243         SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             241

TABLE 244         SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             242

11.4.6    SINGAPORE      242

11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore              242

TABLE 245         SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          242

TABLE 246         SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          243

TABLE 247         SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          243

TABLE 248         SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             244

TABLE 249         SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             244

11.4.7    REST OF ASIA PACIFIC  245

TABLE 250         REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       245

TABLE 251         REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          245

TABLE 252         REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)             246

TABLE 253         REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             246

TABLE 254         REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)    247

11.4.8    ASIA PACIFIC: RECESSION IMPACT        247

11.5       LATIN AMERICA             248

TABLE 255         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       248

TABLE 256         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2021–2028 (USD MILLION)       249

TABLE 257         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          250

TABLE 258        LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          250

TABLE 259         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             251

TABLE 260         LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             251

11.5.1    BRAZIL 252

11.5.1.1 Growth in pharmaceutical R&D to support market growth         252

TABLE 261         BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          252

TABLE 262         BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     253

TABLE 263         BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     253

TABLE 264         BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             254

TABLE 265         BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          254

11.5.2    MEXICO             255

11.5.2.1 Growing number of Phase III clinical trials to drive market growth          255

TABLE 266         MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          255

TABLE 267         MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     256

TABLE 268         MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     256

TABLE 269         MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             257

TABLE 270         MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          257

11.5.3    REST OF LATIN AMERICA          258

TABLE 271         REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION) 258

TABLE 272         REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)    258

TABLE 273         REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)       259

TABLE 274         REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)        259

TABLE 275         REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)            260

11.5.4    LATIN AMERICA: RECESSION IMPACT   260

11.6       MIDDLE EAST  261

11.6.1    GROWING PRESENCE OF PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH        261

TABLE 276         MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)       261

TABLE 277         MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)          262

TABLE 278         MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)          262

TABLE 279         MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             263

TABLE 280         MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)             263

11.6.2    MIDDLE EAST: RECESSION IMPACT       264

11.7       AFRICA 264

11.7.1    GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH        264

TABLE 281         AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2021–2028 (USD MILLION)          265

TABLE 282         AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021–2028 (USD MILLION)     265

TABLE 283         AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2021–2028 (USD MILLION)     266

TABLE 284         AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             266

TABLE 285         AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2021–2028 (USD MILLION)          267

11.7.2    AFRICA: RECESSION IMPACT     267

12          COMPETITIVE LANDSCAPE       268

12.1       INTRODUCTION            268

12.2       STRATEGIES ADOPTED BY KEY PLAYERS           269

FIGURE 38         CLINICAL TRIAL SUPPLIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS            269

12.3       REVENUE SHARE ANALYSIS       270

FIGURE 39         REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)          270

12.4       MARKET SHARE ANALYSIS         271

FIGURE 40         MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)        271

TABLE 286         CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION 272

12.5       COMPANY EVALUATION MATRIX          272

FIGURE 41         CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022            273

12.5.1    STARS  273

12.5.2    EMERGING LEADERS    274

12.5.3    PERVASIVE PLAYERS     274

12.5.4    PARTICIPANTS 274

12.6       COMPANY FOOTPRINT 274

12.6.1    SERVICE FOOTPRINT OF TOP 25 COMPANIES   274

TABLE 287         CLINICAL TRIAL SUPPLIES MARKET: COMPANY SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS            274

12.6.2    REGIONAL FOOTPRINT OF TOP 25 COMPANIES             276

TABLE 288         CLINICAL TRIAL SUPPLIES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS       276

12.7       COMPANY EVALUATION MATRIX: START-UPS/SMES     277

FIGURE 42         CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022     277

12.7.1    PROGRESSIVE COMPANIES       277

12.7.2    STARTING BLOCKS       278

12.7.3    RESPONSIVE COMPANIES          278

12.7.4    DYNAMIC COMPANIES 278

12.8       COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS   278

TABLE 289         CLINICAL TIAL SUPPLIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS           278

TABLE 290         CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 279

12.9       COMPETITIVE SCENARIO AND TRENDS             280

12.9.1    SERVICES LAUNCHES & APPROVALS     280

TABLE 291         CLINICAL TRIAL SUPPLIES MARKET: SERVICE LAUNCHES, JANUARY 2021–AUGUST 2023     280

12.9.2    DEALS  280

TABLE 292         CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2021–JULY 2023          280

12.9.3    OTHER DEVELOPMENTS           282

TABLE 293         CLINICAL TRIAL SUPPLIES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2023           282

13          COMPANY PROFILES    283

(Business overview, Services offered, Recent Developments, MNM view)*

13.1       KEY MARKET PLAYERS 283

13.1.1    THERMO FISHER SCIENTIFIC, INC.         283

TABLE 294         THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW      283

FIGURE 43         THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)   284

13.1.2    CATALENT, INC.            289

TABLE 295         CATALENT, INC.: BUSINESS OVERVIEW 289

FIGURE 44         CATALENT, INC.: COMPANY SNAPSHOT (2022) 290

13.1.3    EUROFINS SCIENTIFIC  295

TABLE 296         EUROFINS SCIENTIFIC: BUSINESS OVERVIEW    295

FIGURE 45         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)    296

13.1.4    PIRAMAL PHARMA SOLUTIONS 298

TABLE 297         PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW  298

FIGURE 46         PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)              299

13.1.5    PRA HEALTH SCIENCES (A SUBSIDIARY OF ICON PLC)  301

TABLE 298         PRA HEALTH SCIENCES: BUSINESS OVERVIEW  301

FIGURE 47         ICON PLC: COMPANY SNAPSHOT (2022)             302

13.1.6    MARKEN (A SUBSIDIARY OF UPS)           304

TABLE 299         UPS: BUSINESS OVERVIEW         304

FIGURE 48         UPS: COMPANY SNAPSHOT (2022)         305

13.1.7    PAREXEL INTERNATIONAL (MA) CORPORATION           307

TABLE 300         PAREXEL INTERNATIONAL (MA) CORPORATION: BUSINESS OVERVIEW        307

13.1.8    BIOCAIR             310

TABLE 301         BIOCAIR: BUSINESS OVERVIEW 310

13.1.9    ALMAC GROUP 312

TABLE 302         ALMAC GROUP: BUSINESS OVERVIEW  312

13.1.10  SHARP SERVICES, LLC  314

TABLE 303         SHARP SERVICES, LLC: BUSINESS OVERVIEW     314

13.1.11  PCI PHARMA SERVICES 315

TABLE 304         PCI PHARMA SERVICES: BUSINESS OVERVIEW   315

13.1.12  NUVISAN           317

TABLE 305         NUVISAN: BUSINESS OVERVIEW             317

13.1.13  LONZA GROUP 319

TABLE 306         LONZA GROUP: BUSINESS OVERVIEW   319

FIGURE 49         LONZA GROUP: COMPANY SNAPSHOT (2022)   320

13.2       OTHER PLAYERS           321

13.2.1    OCT GROUP LLC           321

13.2.2    COREX LOGISTICS LIMITED      322

13.2.3    ACNOS PHARMA GMBH              323

13.2.4    CLINICAL SERVICES INTERNATIONAL  324

13.2.5    KLIFO   325

13.2.6    CLINIGEN LIMITED       326

13.2.7    ANCILLARE LP 327

13.2.8    N-SIDE 328

13.2.9    ADALLEN PHARMA       329

13.2.10  DURBIN             330

13.2.11  RECIPHARM AB 331

13.2.12  IPS PHARMA     332

*Details on Business overview, Services offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14          APPENDIX         333

14.1       DISCUSSION GUIDE      333

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             337

14.3       CUSTOMIZATION OPTIONS      339

14.4       RELATED REPORTS       339

14.5       AUTHOR DETAILS         340